Another study conducted in China demonstrated that a regimen of camrelizumab, apatinib (a VEGFR-2 inhibitor), and HAIC was effective and safe for patients with BCLC stage C HCC (23). The gene discussed is KDR; the disease is hepatocellular carcinoma.